AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34459774
Drug: Daily infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily infusion volume
Trial: 34559129
Drug: Zhen Wu
RxNorm normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhen Wu Decoction (ZWD) with guideline directed medical therapies
Trial: 34559129
Drug: ZWD-granules simulations
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZWD-granules simulations with guideline directed medical therapies
Trial: 35413644
Drug: Huangkui capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huangkui capsule (HKC) 2.5 g, TID
Trial: 35413644
Drug: Zicuiyin decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zicuiyin decoction (ZCY) crude drug amount 75 g, 150 ml, BID
Trial: 32709230
Drug: Real-time monitoring
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time monitoring and just-in-time SMS medication reminders
Trial: 32709230
Drug: Generic weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic weekly SMS reminders
Trial: 32467417
Drug: GSK2862277 (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2862277 (26 mg nebulised dose)
Trial: 32740347
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin II receptor blocker (ARB)
Trial: 36442902
Drug: Home-based multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based multidisciplinary interventions (intensive stage for 6 weeks and maintenance stage for 6 weeks) including health education, follow-up, behaviour guide, social support, skill training, coping with adverse drug reactions, and problem-solving.
Trial: 34298035
Drug: IM trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM trivalent inactivated influenza vaccine
Trial: 34298035
Drug: imi+IM (IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imi+IM (IM vaccine after topical imiquimod)
Trial: 34298035
Drug: imi+ID (ID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imi+ID (ID vaccine after topical imiquimod)
Trial: 35845031
Drug: Aggressive lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive lactated Ringer's (LR) infusion
Trial: 35845031
Drug: Aggressive normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive normal saline (NS) infusion
Trial: 33620419
Drug: GDC‐0334 (TRPA1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC‐0334 (TRPA1 antagonist)
Trial: 32072735
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg/day plus saxagliptin 5 mg/day plus metformin
Trial: 35742280
Drug: Square-stepping exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Square-stepping exercise (SSE) program, performed for 70 min per session, twice a week, for 12 weeks
Trial: 36088952
Drug: Oral amoxicillin–clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin–clavulanic acid (75 mg/kg amoxicillin plus 18.75 mg/kg clavulanic acid, given daily in three doses for 7 days)
Trial: 36088952
Drug: Oral amoxicillin–clavulanic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin–clavulanic acid
Trial: 34873188
Drug: Cost compensation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost compensation (CC)
Trial: 33248603
Drug: 0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg natural ASTA
Trial: 33248603
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg natural ASTA
Trial: 33248603
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg natural ASTA
Trial: 33248603
Drug: 80 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg natural ASTA
Trial: 33248603
Drug: 160 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/kg natural ASTA
Trial: 36226385
Drug: Education intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Education intervention (verbal explanation and demonstration of inhaler technique with metered-dose inhaler using a mannequin)
Trial: 35675658
Drug: 8-Week Self-administered
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-Week Self-administered Home-Based Virtual Reality Program
Trial: 32443695
Drug: Aronia melanocarpa
RxNorm normalized name: ARONIA MELANOCARPA FRUIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aronia melanocarpa juice (AMJ) treatment, 1.17 g/100 mL polyphenols
Trial: 32443695
Drug: low‐polyphenol Aronia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐polyphenol Aronia melanocarpa juice (dAMJ) treatment, 0.29 g/100 mL polyphenols
Trial: 33736920
Drug: GC3110A (quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC3110A (quadrivalent inactivated split-virion influenza vaccine)
Trial: 33736920
Drug: Control TIV
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control TIV (inactivated trivalent influenza vaccine)
Trial: 32130742
Drug: Treatment 0
RxNorm normalized name: Santalia Spot Treatment 0.02 MG/MG Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 0
Trial: 34784577
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg plus androgen deprivation therapy (ADT)
Trial: 34784577
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus androgen deprivation therapy (ADT)
Trial: 34759176
Drug: Difluprednate 0.05%
RxNorm normalized name: DIFLUPREDNATE 0.05% EMULSION,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difluprednate 0.05% nanoemulsion (DIFL) twice a day
Trial: 34759176
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1% + phenylephrine hydrochloride 0.12% suspension (PRED) 4 times a day
Trial: 33258534
Drug: Oral α-lipoic
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral α-lipoic acid (ALA) 300 mg daily for 6 months + NB-UVB phototherapy
Trial: 36027238
Drug: Caffeinated drink
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated drink (3 mg/kg)
Trial: 36418946
Drug: 3 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ug/kg intranasal DEX plus 0.2 mg/Kg oral midazolam
Trial: 36418946
Drug: 2 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ug/kg intranasal DEX plus 0.2 mg/Kg oral Midazolam
Trial: 33420214
Drug: Subcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous and intraperitoneal analgesia
Trial: 33420214
Drug: Subcutaneous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous analgesia and intraperitoneal placebo
Trial: 33420214
Drug: Subcutaneous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous placebo and intraperitoneal analgesia
Trial: 33420214
Drug: Subcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous and intraperitoneal placebo
Trial: 35396310
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion from 20:00 to 08:00 post-surgery
Trial: 33327266
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase combined with edaravone
Trial: 33327266
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis of alteplase
Trial: 35472628
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV epinephrine infusion (0.00375 mg/kg/min) with placebo IV normal saline (NS) boluses every 4 min
Trial: 35472628
Drug: Continuous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous placebo IV NS infusion with IV epinephrine boluses (0.015 mg/kg) every 4 min
Trial: 35472628
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV NS for both infusion and boluses
Trial: 32329069
Drug: Nomogram integrating
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nomogram integrating epigenetic signature, pathological stage, and postoperative chemotherapy
Trial: 32329069
Drug: External validation
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External validation series (combination of GSE17538, GSE33113, GSE37892)
Trial: 35784723
Drug: Molnupiravir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir (800 mg) plus basic treatment for 5 days (BID)
Trial: 35784723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only basic treatment)
Trial: 39601078
Drug: Molnupiravir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molnupiravir (800 mg)
Trial: 32493478
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days (total 14 days)
Trial: 32493478
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 500 mg orally daily for 3 days then 250 mg orally daily for 11 days (total 14 days)
Trial: 36032243
Drug: TRI 360TM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRI 360TM capsules twice a day
Trial: 35918281
Drug: Videographic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videographic and plaque disclosing tablets (PDT)
Trial: 35918281
Drug: Plaque disclosing
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plaque disclosing tablets (PDT)
Trial: 33044886
Drug: Plyometric training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plyometric training program (twice/week over three months plus traditional physical rehabilitation)
Trial: 33044886
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical rehabilitation program (45 minutes/session, twice/week for three months)
Trial: 36154278
Drug: Gemcitabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine monotherapy (5 months)
Trial: 35322144
Drug: 8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/day of gluten for 2 weeks; gluten-tolerating subjects received 16 g/day for 2 weeks and then 32 g/day for a further 2 weeks
Trial: 34992749
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care and Treatment Advice (UC+TA)
Trial: 32803439
Drug: Preoperative submucosal
RxNorm normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative submucosal corticosteroid injection (n = 16), 8 mg/2 ml dexamethasone 21‐phosphate
Trial: 32803439
Drug: Postoperative non‐steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative non‐steroid anti‐inflammatory drug therapy (n = 17), 25 mg dexketoprofen trometamol
Trial: 32528568
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg once daily (30 mg for creatinine clearance 15-50 mL/min, weight ≤ 60 kg, and/or concomitant use of P-glycoprotein inhibitor)
Trial: 33586583
Drug: Curcuma longa
RxNorm normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma longa L. (500 mg/day with piperine 5 mg)
Trial: 32605501
Drug: 1% 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% 5‐fluorouracil cream
Trial: 32605501
Drug: 5% 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5‐fluorouracil cream
Trial: 34996820
Drug: Intravenous ketorolac,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac, 10 mg, three times daily for a maximum of 5 days
Trial: 32178430
Drug: Agility training
RxNorm normalized name: AGIL-FA
DrugBank: AGIL-FA (DB16973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agility training (supervised, group-based, twice a week for one year)
Trial: 32737893
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1000 mg intravenous)
Trial: 35820112
Drug: Intensive multimodality
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage II-III patients.
Trial: 35820112
Drug: Intensive multimodality
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage IVa patients.
Trial: 35820112
Drug: Intensive multimodality
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive multimodality therapy including four cycles of chemotherapy and one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem-cell support for stage IVb patients.
Trial: 33369684
Drug: General sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General sensorimotor training (group therapy)
Trial: 34542910
Drug: Self-administered anonymous
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered anonymous questionnaire assessing misconceptions about oral radiology and medicine
Trial: 34119566
Drug: Intravenous Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Clonidine Group (IVCG)
Trial: 37517579
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (BMT)
Trial: 33058795
Drug: Cefiderocol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefiderocol (2 g every 8 hours for 7–14 days)
Trial: 33058795
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy (pre-specified by the investigator, maximum of three drugs for 7–14 days)
Trial: 32075010
Drug: Ketogenic state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketogenic state (βHB ≥0.3 mmol/L)
Trial: 34824982
Drug: Internet-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioral therapy (ICBT) including psychoeducation, cognitive restructuring, attentional training, and exposure.
Trial: 36409435
Drug: TAK-931 80
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-931 80 mg tablet
Trial: 36409435
Drug: TAK-931 80
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-931 80 mg PIC
Trial: 36409435
Drug: TAK-931 50
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-931 50 mg PIC QD
Trial: 32091032
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy (ILIT) with pollen extracts, 3 intralymphatic inguinal injections before the first pollen season.
Trial: 32091032
Drug: Intralymphatic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic immunotherapy (ILIT) with pollen extracts.
Trial: 34694872
Drug: Telacebec (Q203)
RxNorm normalized name: Telacebec
DrugBank: Telacebec (DB17754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telacebec (Q203) 10 to 800 mg
Trial: 34694872
Drug: Telacebec (Q203)
RxNorm normalized name: Telacebec
DrugBank: Telacebec (DB17754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telacebec (Q203) 10 to 800 mg (fed condition)
Trial: 35401774
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) + physiotherapy treatment (PT)
Trial: 32213042
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy for 3 days or less
Trial: 32213042
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy for 4 days or more
Trial: 36067369
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (cholecalciferol) in men with baseline 25‐hydroxyvitamin D <20 ng/mL
Trial: 34966900
Drug: Abatacept (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (125 mg subcutaneous every week)
Trial: 35792520
Drug: Inotrope therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inotrope therapy
Trial: 33452192
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (chemotherapy)
Trial: 32398341
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days antibiotic treatment
Trial: 32398341
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days antibiotic treatment
Trial: 32910135
Drug: Faricimab (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab (dosing every four months)
Trial: 32910135
Drug: Faricimab (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faricimab (dosing quarterly)
Trial: 36493791
Drug: Bimekizumab 160
RxNorm normalized name: Bimekizumab 160 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 160 mg every 4 weeks (after switch from placebo at week 16)
Trial: 36493791
Drug: Overall treatment-emergent
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment-emergent adverse events
Trial: 35780106
Drug: SAYGo airway
RxNorm normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAYGo airway topical anesthesia and superior laryngeal nerve (SLN) block combined with transtracheal injection (TTI)
Trial: 35780106
Drug: SAYGo airway
RxNorm normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAYGo airway topical anesthesia and SLN block combined with TTI
Trial: 33939193
Drug: Systemic amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic amoxicillin (AMX) plus metronidazole (MTZ)
Trial: 34322547
Drug: Single-inhaler triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-inhaler triple therapy (12.5 μg glycopyrronium, 12 μg formoterol, 250 μg fluticasone)
Trial: 34322547
Drug: Open-triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-triple therapy (50 μg glycopyrronium co-administered with 12 μg formoterol and 250 μg fluticasone)
Trial: 34357480
Drug: Oro-buccal administered
RxNorm normalized name: Oro Clense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oro-buccal administered cannabidiol-dominant anti-inflammatory formulation (MDCNB-02)
Trial: 39506737
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy (CST)
Trial: 616039576
Drug: Eye gel
RxNorm normalized name: EYE GEL
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eye gel (FC formulated as eye gel)
Trial: 33766150
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus olanzapine (n = 64)
Trial: 33766150
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus placebo (n = 62)
Trial: 32812840
Drug: Stuttering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuttering treatment integrated with evidence-based parenting support (EBPS) for children with eADHD (eADHDintegrated)
Trial: 32812840
Drug: Stuttering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuttering treatment only for children with eADHD (eADHDstandard)
Trial: 32812840
Drug: Stuttering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuttering treatment only for children without eADHD (No-eADHDstandard)